First-Line Medications for Lupus

Treatment Algorithm for Lupus

The European League Against Rheumatism recommends hydroxychloroquine as the first-line medication for all patients with systemic lupus erythematosus (SLE), regardless of disease severity or organ involvement, at a dose not exceeding 5 mg/kg real body weight 1, 2
Ophthalmological screening should be performed at baseline, after 5 years, and yearly thereafter to monitor for retinal toxicity, as recommended by the European League Against Rheumatism 2
Hydroxychloroquine has been shown to improve outcomes by reducing renal flares and limiting accrual of renal and cardiovascular damage, with a strength of evidence rated as high by the European League Against Rheumatism 3

For mild disease, the European League Against Rheumatism recommends hydroxychloroquine alone as sufficient, with low-dose glucocorticoids (prednisone <7.5 mg/day) added for symptom control 1, 2
For moderate to severe disease, the European League Against Rheumatism recommends adding glucocorticoids at doses dependent on disease severity, with pulses of intravenous methylprednisolone (250-1000 mg/day for 1-3 days) used initially, and oral prednisone minimized to less than 7.5 mg/day for chronic maintenance 2
For organ-threatening disease, the European League Against Rheumatism recommends including immunosuppressive agents in initial therapy, with mycophenolate mofetil or low-dose intravenous cyclophosphamide recommended as initial treatment for lupus nephritis 2, 4

Regular monitoring of disease activity is essential, with visits scheduled every 2-4 weeks for the first 2-4 months after diagnosis or flare, and assessment including body weight, blood pressure, serum creatinine, eGFR, serum albumin, proteinuria, urinary sediment, complement levels, and anti-dsDNA antibody levels, as recommended by the European League Against Rheumatism 3
Long-term follow-up should continue at least every 3-6 months, with medication adherence critical to preventing disease flares, as emphasized by the European League Against Rheumatism 3

For patients with inadequate response to standard therapy, the European League Against Rheumatism recommends considering belimumab as add-on treatment, with a strength of evidence rated as moderate 2, 4
In organ-threatening disease refractory to standard immunosuppressives, the European League Against Rheumatism recommends considering rituximab, with a strength of evidence rated as low 2, 4
Triple immunosuppressive regimens (belimumab with glucocorticoids and either mycophenolate or reduced-dose cyclophosphamide) may benefit patients with repeated kidney flares, as suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline society 5